Curis, Inc.
61 Moulton Street
Cambridge
Massachusetts
02138
Tel: 617-876-0086
Fax: 617-876-0866
Website: http://www.curis.com/
382 articles with Curis, Inc.
-
Curis Announces Advancement to the 200mg BID Cohort in the CA-4948 Study
4/8/2019
Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced today that it has begun dosing patients in the 5th cohort (200mg BID; total daily dose of 400mg) in the Phase 1 trial of CA-4948, an orally available small molecule inhibitor of IRAK4, for treatment of patients with non-Hodgkin lymphoma,
-
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - April 5, 2019
4/5/2019
Curis, Inc. announced that on April 2, 2019, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase 150,000 shares of Curis common stock to a new employee, with a grant date of April 2, 2019.
-
Public perception of the industry can be a bit confusing. Life Science Leader recently pulled together several biopharma executives for a round table discussion of the biopharma industry’s public perception—generally bad—and what might be able to do about it.
-
Curis Reports Fourth Quarter and Year-End 2018 Financial Results
3/26/2019
Management to host conference call today at 4:30 p.m. ET
-
Curis to Release Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on March 26, 2019
3/25/2019
Curis, Inc. announced that the Company will release its fourth quarter and full-year 2018 financial results on Tuesday, March 26, 2019, after the close of the US markets.
-
Curis Sells Portion of Erivedge Royalties to Oberland Capital for up to $135.7 million
3/25/2019
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into an agreement with funds managed by Oberland Capital Management, LLC ("Oberland Capital") for up to $135.7 million in exchange for selling rights to a portion of royalty revenues on worldwide net sales of Erivedge.
-
Curis Announces Presentation at Cowen & Company 39th Annual Healthcare Conference
3/4/2019
Curis, Inc. announced that James Dentzer, President and Chief Executive Officer, will present at the Cowen & Company 39th Annual Healthcare Conference on Wednesday, March 13th, at 11:20 a.m. – 11:50 a.m. EST in the Berkeley room at the Marriott Copley in Boston, MA.
-
Curis, Inc. to Present at the 2019 BIO CEO & Investor Conference
2/4/2019
Curis, Inc. today announced that James Dentzer, President and Chief Executive Officer, will present at the 2019 BIO CEO & Investor Conference on Tuesday, February 12th, at 10:30 a.m. EST in the Hudson/Empire Room at the Marriott Marquis in New York City.
-
First Mesothelioma Patient Dosed in CA-170 Study
1/24/2019
Curis, Inc. today announced that the first mesothelioma patient has been enrolled and dosed in the Phase I study of CA-170.
-
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) on January 4, 2019
1/4/2019
Curis, Inc. announced that on January 2, 2019, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase 30,000 shares of Curis common stock to a new employee, with a grant date of January 2, 2019
-
Curis to Present at the 60th Annual Meeting of the American Society of Hematology
11/20/2018
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced three upcoming poster presentations at the 60th annual meeting of the American Society of Hematology.
-
Curis to Present at 33rd Society for Immunotherapy of Cancer Annual Meeting and Cowen IO NEXT Summit
11/7/2018
Curis, Inc. today announced upcoming presentations at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting and participation in an analyst-moderated Q&A panel at Cowen's 2nd Annual IO NEXT Summit.
-
Curis Reports Third Quarter 2018 Financial Results
11/1/2018
New leadership increasing focus on clinical execution
-
Curis to Release Third Quarter Financial Results and Hold Conference Call on November 1, 2018
10/23/2018
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third quarter 2018 financial results on Thursday, November 1, 2018, before the U.S. financial markets open.
-
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) on October 1, 2018
10/5/2018
Curis, Inc. today announced that on October 1, 2018, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase 30,000 shares of Curis common stock to a new employee, with a grant date of October 1, 2018 (the "Q4 2018 Inducement Grant").
-
Movers and Shakers Oct. 1
10/1/2018
Here's a look at who shook things up in the world of pharma and biotech this week. -
The past few days has had a flurry of activity in the industry with leadership changes. Let's take a look at some of those!
-
Curis to Present at the Baird 2018 Global Healthcare Conference
8/28/2018
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company will present at the Baird 2018 Global Healthcare Conference on Wednesday, September 5 at 2:35-3:05 PM in Session III - Empire Ballroom B, Mezzanine Level of the InterContinental New York Barclay in New York.
-
This week, the Business Journals compiled a list of the 25 companies across the United States with the highest median salary for employees. According to the list, median salaries for these companies ranked from $198,000 to $495,000. Of those companies listed, more than half were in the pharma or ...
-
Curis Reports Second Quarter 2018 Financial Results
8/2/2018
Management to host conference call today at 8:30 a.m. EDT